S. Ad

发表

Monocytes Contribute to High Renal Allograft Rejection Rates when Alemtuzumab is Utilized as an Induction Agent: A Retrospective Study

M. Rees, J. Ortiz, Luke Mugge, 2018 .

Alemtuzumab Equalizes Short Term Outcomes in High Risk PRA Patients: Long Term Outcomes Suffer

M. Rees, O. Ekwenna, J. Ortiz, 2017 .